During the past decade, University General Hospital of Heraklion conducted 100 clinical trials. In the 10-year time frame, 100 clinical trials started and 48 clinical trials were completed, i.e. on average, 48% percent of trials that started reached the finish line to date. In the past 5 years, 54 clinical trials started and 38 clinical trials were completed. i.e. 70.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University General Hospital of Heraklion" #1 sponsor was "Hellenic Oncology Research Group" with 22 trials, followed by "Boehringer Ingelheim" with 14 trials sponsored, "Amgen" with 13 trials sponsored, "Hoffmann-La Roche" with 13 trials sponsored and "Eli Lilly and Company" with 13 trials sponsored. Other sponsors include 80 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University General Hospital of Heraklion" #1 collaborator was "University Hospital of Crete" with 18 trials as a collaborator, "Eli Lilly and Company" with 4 trials as a collaborator, "AstraZeneca" with 3 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 2 trials as a collaborator and "Incyte Corporation" with 2 trials as a collaborator. Other collaborators include 36 different institutions and companies that were collaborators in the rest 45 trials.

According to Clinical.Site data, the most researched conditions in "University General Hospital of Heraklion" are "Breast Cancer" (21 trials), "Idiopathic Pulmonary Fibrosis" (7 trials), "Carcinoma, Non-Small-Cell Lung" (6 trials), "Ulcerative Colitis" (5 trials) and "Atrial Fibrillation" (4 trials). Many other conditions were trialed in "University General Hospital of Heraklion" in a lesser frequency.

Most popular intervention types in "University General Hospital of Heraklion" are "Drug" (132 trials), "Other" (14 trials), "Device" (4 trials), "Biological" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (41 trials), "Docetaxel" (13 trials), "Carboplatin" (11 trials), "Paclitaxel" (8 trials) and "Bevacizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "University General Hospital of Heraklion" are 130 trials for "All" genders, 22 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "University General Hospital of Heraklion". undefined are not yet recruiting, 31 are recruiting, 23 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 77 completed trials in University General Hospital of Heraklion, undefined suspended trials, and 22 terminated clinical trials to date.

Out of the total trials that were conducted in University General Hospital of Heraklion, 6 "Phase 1" clinical trials were conducted, 44 "Phase 2" clinical trials and 81 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 5 trials that are defined as “Not Applicable".